MaxCyte, Inc. - Common Stock (MXCT)
3.4300
-0.1100 (-3.11%)
Maxcyte Inc is a biotechnology company focused on developing and commercializing innovative cell-based therapies and drug discovery solutions
The company specializes in providing its proprietary cell-engineering platform, which enables the rapid development and manufacturing of complex, cell-based therapeutics. By facilitating the delivery of genetic material into various types of cells, Maxcyte aims to enhance the capabilities of researchers and developers in the biopharmaceutical industry, ultimately contributing to the advancement of new treatments for a variety of diseases, including cancer and genetic disorders.

Stocks surged higher as investors reacted positively to dovish tariff news; next week will be highlighted by the Federal Reserve meeting and some tech earnings
Via MarketBeat · January 25, 2025

MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.
Via MarketBeat · January 23, 2025

MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024

Via Benzinga · May 8, 2024

Via Benzinga · May 8, 2024

MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024

Shares of Taysha Gene Therapies, Inc. (NASDAQTSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results.
Via Benzinga · March 20, 2024

U.S. stock futures were slightly lower this morning, with the Dow futures falling by around 0.1% on Wednesday.
Via Benzinga · March 20, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · March 13, 2024

U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.
Via Benzinga · March 13, 2024

Via Benzinga · March 12, 2024

U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.
Via Benzinga · January 9, 2024

MaxCyte Inc (NASDAQMXCT) shares are trading higher by over 9% after the company disclosed strong preliminary Q4 and full-year
Via Benzinga · January 9, 2024

Companies Reporting Before The Bell • Aurora Mobile (NASDAQJG) is likely to report earnings for its fourth quarter.
Via Benzinga · March 12, 2024

Via Benzinga · January 8, 2024

Via Benzinga · December 6, 2023

The biotech company reduced full-year guidance and expects so-so third-quarter revenue.
Via The Motley Fool · October 5, 2023

MaxCyte Inc (NASDAQMXCT) shares plummeted after the company released preliminary Q3 revenue of $7.8 million – 8.0 million, a Y/Y decrease of 25 -27%, due to continued reduced
Via Benzinga · October 5, 2023

U.S. stocks traded slightly lower toward the end of trading, with the Dow Jones index falling around 40 points on Thursday. The Dow traded down 0.12% to 33,088.44 while the NASDAQ fell 0.23% to 13,206.10. The S&P 500 also fell, dropping, 0.23% to 4,253.86.
Via Benzinga · October 5, 2023

Via Benzinga · October 5, 2023

Gainers Orchard Therapeutics plc (NASDAQORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS.
Via Benzinga · October 5, 2023

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.45% to 32,980.31 while the NASDAQ fell 0.62% to 13,154.24. The S&P 500 also fell, dropping, 0.57% to 4,239.60.
Via Benzinga · October 5, 2023